Evidence map›Paper›PMID 41378821›Full record

ArticleACS nano2025

Optimizing Exosome Lipid Hybrid Nanoparticles for Enhanced siRNA Delivery and Improved Therapeutic Anticancer Efficacy In Vivo.

Hend Mohamed Abdel-Bar, Steven Tandiono, Revadee Liam-Or, Calvin C L Cheung, Osama W M Hassuneh, Qingyang Lyu, Yue Qin, Shunping Han, Nadia Rouatbi, Julie Tzu-Wen Wang and 2 more

Abstract read
In one paragraph

Article in ACS nano, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed.

  1. Review
  2. Review
  3. Review
  4. Review
  5. Review
  6. Review
  7. Review
  8. Article
  9. Review
  10. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Hend Mohamed Abdel-BarInstitute of Pharmaceutical Science, King's College London, Franklin-Wilkins Building, 150 Stamford Street, London SE1 9NH, U.K.ORCID 0000-0001-5833-9267
Steven TandionoInstitute of Pharmaceutical Science, King's College London, Franklin-Wilkins Building, 150 Stamford Street, London SE1 9NH, U.K.
Revadee Liam-OrInstitute of Pharmaceutical Science, King's College London, Franklin-Wilkins Building, 150 Stamford Street, London SE1 9NH, U.K.
Calvin C L CheungDepartment of Pharmacology and Pharmacy, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Hong Kong, Hong Kong Special Administrative Region999077, China.
Osama W M HassunehDepartment of Pharmacology and Pharmacy, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Hong Kong, Hong Kong Special Administrative Region999077, China.
Qingyang LyuDepartment of Pharmacology and Pharmacy, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Hong Kong, Hong Kong Special Administrative Region999077, China.
Yue QinInstitute of Pharmaceutical Science, King's College London, Franklin-Wilkins Building, 150 Stamford Street, London SE1 9NH, U.K.
Shunping HanInstitute of Pharmaceutical Science, King's College London, Franklin-Wilkins Building, 150 Stamford Street, London SE1 9NH, U.K.
Nadia RouatbiInstitute of Pharmaceutical Science, King's College London, Franklin-Wilkins Building, 150 Stamford Street, London SE1 9NH, U.K.
Julie Tzu-Wen WangInstitute of Pharmaceutical Science, King's College London, Franklin-Wilkins Building, 150 Stamford Street, London SE1 9NH, U.K.
Adam A WaltersInstitute of Pharmaceutical Science, King's College London, Franklin-Wilkins Building, 150 Stamford Street, London SE1 9NH, U.K.
Khuloud T Al-JamalInstitute of Pharmaceutical Science, King's College London, Franklin-Wilkins Building, 150 Stamford Street, London SE1 9NH, U.K.ORCID 0000-0001-5165-2699

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Exosome lipid hybrid nanoparticles (ELNs) have emerged as promising drug delivery vehicles, integrating the innate targeting capabilities of exosomes with efficient cytosolic delivery of lipid nanoparticles. However, despite growing interest, the development of ELNs for nucleic acid delivery remains a formidable challenge, compounded by diverse production methods and a lack of systematic approaches to optimize their formulation and performance. This study employed a Box-Behnken design and two fabrication methods: freeze-thaw and sonication, to optimize the formulation of ELNs derived from exosomes of five distinct cancer cells. Formulation criteria focused on maximizing the fusion efficiency while minimizing particle size. The impact of the fusion method on cellular association and gene silencing of promising therapeutic targets, CD24, CD44, and CD47, was evaluated. The optimized formulations were subsequently assessed for therapeutic efficacy in 4T1 and B16F10 tumor models. Through careful manipulation of formulation variables, we obtained optimal ELNs with fusion efficiencies exceeding 50% and particle sizes under 170 nm while preserving exosomal markers CD9, CD63, and CD81. Cellular association studies revealed that ELNs specifically targeted their parental cell line, achieving ∼2.5-fold higher siRNA association compared to LNPs. Furthermore, the optimized ELNs facilitated the delivery of therapeutic siRNAs, resulting in robust gene silencing and consequently improved the in vitro macrophage-mediated phagocytosis of treated cancer cells. In vivo studies using 4T1 and B16F10 tumor models highlighted the enhanced therapeutic potential of the optimized ELNs, as evidenced by significant tumor targeting and growth inhibition. These findings underscore the importance of systematic formulation and method optimization in advancing ELNs as effective nucleic acid delivery platforms for cancer therapy.

Indexed as

ExosomesGene SilencingLiposomesNanoparticle Drug Delivery SystemNanoparticlesNeoplasmsRNA, Small InterferingAnimalsCD24 AntigenCD47 AntigenHyaluronan ReceptorsMelanoma, ExperimentalMiceCD24 AntigenCD47 AntigenHyaluronan ReceptorsLipid NanoparticlesLiposomesNanoparticle Drug Delivery SystemRNA, Small InterferingCD24CD44CD47DoEextracellular vesicleslipid nanoparticlestriple negative breast cancer

Identifiers

PMID41378821
PMCPMC12774390

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.